Aktis Oncology, Inc.
Aktis Oncology, Inc. (AKTS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
akts · stock forecast · 7 analysts (3M) · FMP · updated May 13, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$35.00
Consensus
$33.00
+74.0% upside
Low
$31.00
Median: $33 · Last Close: $18.97
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$33.00
74.0% upside
High Target
$35
84.5%
Low Target
$31
63.4%
Current Price
$18.97
as of today
Based on analyst price targets, the AKTS stock price prediction for the next 12 months ranges from $31 to $35. The consensus AKTS price forecast of $33.00 implies 74.0% upside from the current price of $18.97.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $18.92 | ↓ 0.25% |
1-day model range: $18.8–$19.05. Peak: $19.05 (-0.25%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AKTS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-01-04 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-09-07 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-09-07 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2023-05-09 | Roth MKM | Maintains | Buy→Buy |
| 2023-05-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-11-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-09-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-05-03 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Aktis Oncology, Inc. (AKTS) stock. Of the recent 17 rating actions, 1 were upgrades and 4 were downgrades. 7 analysts currently cover AKTS.
Analyst Recommendation Trends
AKTS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↑ 591.5% YoY
Revenue Next Year
$15M
↓ 28.4% YoY
EPS This Year
$-1.62
EPS Next Year
$-2.28
↑ 40.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast AKTS EPS of $-1.62 for the current fiscal year, based on estimates from 4 analysts. The AKTS revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AKTS stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AKTS price target is $33.00 (+74.0% upside), with an analyst consensus of Buy.
The AKTS short-term stock prediction for tomorrow is $18.92 (-0.25%).
Aktis Oncology, Inc. trades on NASDAQ under the ticker AKTS. The AKTS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.
Frequently asked questions
AKTS forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month AKTS price target is $33.00, with a high forecast of $35.00 and a low of $31.00. The median price target is shown in the chart above when available. This implies +74.0% potential upside from the current price of $18.97.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.